ArticleJournal of managed care & specialty pharmacy2023
Prescription digital therapeutics: Applying Medicaid experience to value assessment and formulary management.
Article in Journal of managed care & specialty pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Diving into the Regulatory Landscape of Digital Therapeutics.Therapeutic innovation & regulatory science · 2026Review
- Digital Therapeutics for Alzheimer's and Parkinson's Diseases: Current Trends and Future Perspectives.Medicinal research reviews · 2026Review
- Current Status and Future Directions in the Development of Digital Therapeutic Interventions for Neurodevelopmental Disorders.Clinical pharmacology and therapeutics · 2025Review
- Approved trends and product characteristics of digital therapeutics in four countries.NPJ digital medicine · 2025Article
- Download to heal: navigating the pixelated path of digital therapeutics in psychiatric care.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025Review
- Artificial Intelligence in Cardiovascular Care-Part 2: Applications: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2024Review
- Stress reduction and psychological therapy for IBS: a scoping review.Frontiers in gastroenterology (Lausanne, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital therapeutics (DTx) are a rapidly growing therapeutic category with more than 150 clinical trials evaluating US Food and Drug Administration-regulated DTx to develop additional evidence by the end of 2022. Investments in DTx development have doubled since 2019, reaching $14.7 billion in 2021. Prescription DTx are regulated by the US Food and Drug Administration and require demonstration of efficacy and safety prior to commercialization and reimbursement by payers. Drawing insights from the Massachusetts Medicaid program's early experience with prescription DTx, we provide an overview of this new category of therapeutics and suggest a roadmap for payers and policymakers to evaluate the value of prescription DTx for their member population. Finally, we propose solutions to potential challenges that may be encountered in the DTx coverage and reimbursement management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.